Skip to Main Content

Jou Group


Roger Jou and his team work to identify safe, effective, and community-based interventions for the core symptoms of autism. Interventions can be strictly biological in nature and the group conducts multiple clinical trials on new medications being developed in the healthcare industry. Interventions can also be more practical and psychosocial in character. The group provides ongoing clinical care and works with communities to find new ways to provide and/or supplement routine treatment to individuals living with autism.

The Jou Lab collaborates with other research teams in order to characterize the neurobiology of autism by studying brain structure and underlying connections using neuroimaging technology. In addition, community service is a vital part of our work and an online community has been developed to support it:

The Jou group is led by Dr. Roger J. Jou, Assistant Clinical Professor in the Child Study Center.

Participant Eligibility/Benefits

  • Children, adolescents and adults living with autism and their caregivers
  • Each study has different eligibility requirements and potential benefits
  • Interested individuals are encouraged to call or email to determine qualifications and address any questions

Research Interest

Psychopharmacology and practical, real life, psychosocial interventions for adults and adolescents living with autism

IRB Study Titles

  • A Double Blind Randomized Placebo Controlled Study of CM-AT for the Treatment of Autism in Children with All Levels of Fecal Chymotrypsin (HIC# 1505015948)
  • An Open-Label Extension Study of CM-AT for the Treatment of Children with Autism (HIC# 1601017019)
  • EPITRA-15-004: Analysis of the Glutathione Cycle in Children with Autism (HIC# 1510016590)
  • A Phase II Multi-Center, Randomized, Double Blind, 24-Week, 3-Arm, Parallel Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of RO5285119 in Children and Adolescents Age 5-17 with Autism Spectrum Disorder (ASD) (HIC# 1609018473)
  • A Multi-Center, Randomized, Double Blind, 12-Week, Parallel Group, Placebo-Controlled, Proof of Concept Study to Investigate the Efficacy and Safety of RO5285119 in Individuals with Autism Spectrum Disorders (ASD) (HIC# 1312013193)

Research Team

Collaborating Yale Faculty